On Monday, Ocuphire Pharma, Inc. unleashed in the market their new product titled Ryzumvi. This pharmaceutical ophthalmic solution, with a concentration of 0.75% phentolamine, has been launched across the United States with the help of their partner company, Viatris Inc.
Served as a topical eye drop, Ryzumvi is free of anti-microbial preservatives. It is primarily used to trigger pharmacologically-induced mydriasis, a condition which is typically stimulated by adrenergic agonists or parasympatholytic agents.
Ocuphire and Viatris are bound by a worldwide license agreement, which puts them in a position to co-develop and commercialize Ryzumvi. As stated in the agreement, Ocuphire is eligible to receive regulatory milestones and royalties in conjunction with the commercial performance of Ryzumvi.
